Immix Biopharma Investor Presentation Deck
November 2023, 64 slides
  1. Immix Biopharma
  2. Related Decks
  3. Investor Presentation Decks
the art of precision the science of cure pioneering personalized therapies for oncology and immunology eel leek set ate | Immix Biopharma
disclaimer forward looking statements market data | Immix Biopharma
immix investment highlights teal meaner alfa | Immix Biopharma
world class team of health medicine | Immix Biopharma
genius platform overview genius platform | Immix Biopharma
broad disease applicability of the genius platform | Immix Biopharma
restricts car adoption car | Immix Biopharma
genius platform expand technology cobra binder genius platform | Immix Biopharma
genius platform expand technology cobra binder genius platform | Immix Biopharma
proprietary optimized delivers digital intracellular signaling eliminates reduces duration memorial sloan | Immix Biopharma
proprietary optimized delivers digital intracellular signaling eliminates reduces duration immi | Immix Biopharma
optimal tumor binding while ensuring high expression research | Immix Biopharma
resolves resolving car | Immix Biopharma
is overcoming prolonged and low for | Immix Biopharma
genius technology platform proprietary cobra binding domain is a differentiated innovation | Immix Biopharma
next generation car for multiple myeloma and amyloidosis first car generated by the genius platform | Immix Biopharma
genius technology platform rapidly eliminates relapsed refractory multiple myeloma tumors driving dramatically improved tolerability | Immix Biopharma
genius technology platform rapidly eliminates diseased amyloidosis plasma cells and exits within days blood to cart infusion | Immix Biopharma
nature of amyloidosis | Immix Biopharma
first car in amyloidosis a billion market by wer choice i | Immix Biopharma
only car in exposed multiple myeloma a rapidly growing patient segment newly diagnosed standard of care refractory exposed a rapidly growing patient segment | Immix Biopharma
only car in exposed multiple myeloma a rapidly growing patient segment | Immix Biopharma
clinical development plan through submissions light chain | Immix Biopharma
outpatient access to potentially increases car market by | Immix Biopharma
clinical results demonstrate potential for best in class efficacy safety in soft tissue sarcoma and encouraging efficacy in cancer | Immix Biopharma
upcoming catalysts ria | Immix Biopharma
pipeline summary immix immix immix | Immix Biopharma
entering large markets at a pivotal moment market size why now | Immix Biopharma
potential to disrupt the oncology and immunology categories | Immix Biopharma
lead cell therapy candidate | Immix Biopharma
clinical results demonstrate potential for best in class efficacy safety in light chain amyloidosis tae cardiac renal | Immix Biopharma
clinical results demonstrate potential for best in class efficacy safety in multiple myeloma a billion market by class leading | Immix Biopharma
clinical results demonstrate potential for best in class efficacy safety in multiple myeloma | Immix Biopharma
clinical highlights across patients outpatient car potential | Immix Biopharma
proportion of patients with increased over time in relapsed refractory multiple myeloma | Immix Biopharma
adverse event profile | Immix Biopharma
adverse event profile market | Immix Biopharma
ongoing clinical study design in multiple myeloma | Immix Biopharma
lead candidate chi | Immix Biopharma
tissue specific therapeutic with normalization technology first targeted oncology micelle to achieve small molecule penetration as | Immix Biopharma
preclinical data provides translational rationale combination rationale | Immix Biopharma
clinical trial and supply agreement with for anti immix | Immix Biopharma
pancreatic preclinical mouse model outperforms gem pac | Immix Biopharma
lead candidate imminent clinical trial data regret clinic ors | Immix Biopharma
a data tumor shrinkage in of heavily soft tissue sarcoma patients lag mare am sic teer mar | Immix Biopharma
opportunity soft tissue sarcoma remains an unmet medical need | Immix Biopharma
clinical data month in late stage sarcoma well tolerated oat immix | Immix Biopharma
direct path to line therapy in clinical trial plan cold | Immix Biopharma
preclinical candidates | Immix Biopharma
cell therapy platform genius platform | Immix Biopharma
tissue specific platform normalization technology tissue specific platform oncology application biologic confidential air | Immix Biopharma
glut targeted for cancer | Immix Biopharma
preclinical data in breast cancer immix therapies produce rare tumor shrinkage stability | Immix Biopharma
glut targeted for inflammatory bowel disease a | Immix Biopharma
immix investment highlights teal meaner alfa | Immix Biopharma
appendix | Immix Biopharma
genius platform tissue specific platform genius platform | Immix Biopharma
genius platform process toon | Immix Biopharma
preconditioning regimens cart | Immix Biopharma
relapsed refractory multiple myeloma key inclusion criteria | Immix Biopharma
relapsed refractory multiple myeloma key exclusion criteria | Immix Biopharma
antibodies are currently being investigated as an outpatient therapy may at regions hospital may | Immix Biopharma
market opportunity oncology | Immix Biopharma
opportunity inflammatory bowel disease market company | Immix Biopharma
See More
Immix Biopharma
Investor Presentation Decks
Biotechnology Decks
Healthcare Decks
Explore Topics
Cancer
Tumor
Cell therapy
Clinical trial
Solid tumor
Recent decks by Immix Biopharma
Investor Presentation
March 2024
Investor Presentation
January 2024
Investor Presentation
December 2023
Investor Presentation
November 2023
See all presentations by Immix Biopharma (11 decks)
Related decks
BioNTech
Results
August 2021
BioNTech
Results
May 2021
BioNTech
Results
November 2021
BioNTech
Investor Presentation
August 2022
Mink Therapeutics
IPO
October 2021
Immatics
Investor Presentation
November 2023
Genelux
Investor Presentation
February 2024
BioNTech
Results
March 2021
Recent decks by Immix Biopharma
See all presentations (11 decks)
Investor Presentation
March 2024
Investor Presentation
January 2024
Investor Presentation
December 2023
Investor Presentation
November 2023
BioNTech
Results
August 2021
BioNTech
Results
May 2021
BioNTech
Results
November 2021
BioNTech
Investor Presentation
August 2022
Mink Therapeutics
IPO
October 2021
Immatics
Investor Presentation
November 2023
Genelux
Investor Presentation
February 2024
BioNTech
Results
March 2021
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2024 Slidebook.io